Literature DB >> 1674949

The prevalence of tardive dyskinesia.

M G Woerner1, J M Kane, J A Lieberman, J Alvir, K J Bergmann, M Borenstein, N R Schooler, S Mukherjee, J Rotrosen, M Rubinstein.   

Abstract

A total of 2250 subjects from psychiatric and geriatric settings was examined for abnormal involuntary movements by the same team of trained raters employing a standard examination technique and rating scale. "Spontaneous" dyskinesia rates were 1.3% among 400 healthy elderly people surveyed at senior citizens centers, 4.8% among medical geriatric inpatients and ranged from 0 to 2% among psychiatric patients never exposed to neuroleptics. For samples of neuroleptic-treated patients, prevalence rates ranged from 13.3% among patients at a voluntary psychiatric hospital to 36.1% among state hospital patients. Logistic regression analyses revealed a large effect of age on tardive dyskinesia prevalence and an interaction of age with sex. Among younger subjects, men had higher rates; among subjects over age 40, rates were higher for women. Edentulousness and presence of other neurological disorders were possible contributors to high rates for the elderly. Even with control for age, sex and duration of neuroleptic exposure, prevalence differed markedly across study site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674949

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

2.  Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study.

Authors:  Itzhak Kimiagar; Evgenia Dobronevsky; Tatiana Prokhorov; Ala Miniovitz; Jose M Rabey
Journal:  J Neurol       Date:  2011-11-09       Impact factor: 4.849

Review 3.  Managing antipsychotic-induced tardive dyskinesia.

Authors:  G Gardos
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

Review 4.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

5.  Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro.

Authors:  Luis Ricardo Peroza; Alcindo Busanello; Caroline Queiroz Leal; Jivago Röpke; Aline Augusti Boligon; Daiane Meinerz; Milena Libardoni; Margareth Linde Athayde; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2013-02-02       Impact factor: 3.996

6.  Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.

Authors:  Roselei Fachinetto; Jardel G Villarinho; Caroline Wagner; Romaiana P Pereira; Robson L Puntel; Márcio W Paixão; Antonio L Braga; João Batista Calixto; João B T Rocha; Juliano Ferreira
Journal:  Psychopharmacology (Berl)       Date:  2007-07-20       Impact factor: 4.530

7.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

8.  Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia.

Authors:  Xiang Yang Zhang; Da Chun Chen; Ling Yan Qi; Fang Wang; Mei Hong Xiu; Song Chen; Gui Ying Wu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

Review 9.  Treatment of neurolept-induced tardive dyskinesia.

Authors:  Stacey K Jankelowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

10.  Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study.

Authors:  Rikinkumar S Patel; Zeeshan Mansuri; Amit Chopra
Journal:  Heliyon       Date:  2019-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.